Pixels Hunter / Shutterstock.com
20 February 2024FeaturesEuropeJackie Mulryne and Beatriz San Martin

What does the UK’s pro-innovation approach to AI mean for life sciences companies?

It remains to be seen whether AI developers in the medical sector will benefit from the UK’s ‘flexible’ regulatory environment or find the lack of cohesion detrimental, say Jackie Mulryne and Beatriz San Martin of Arnold & Porter.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Europe
9 June 2026   In the second of a series of interviews with women judges at the Unified Patent Court, Carine Gillet shares her views with Sarah Speight on encouraging more women into technical judicial careers, how equipped the court is to handle life sciences disputes, and more.
Europe
2 June 2026   The court has officially opened its mediation and arbitration forum, with technology, life sciences and manufacturing companies expected to be among its earliest users—particularly in FRAND and licensing cases.
Europe
28 May 2026   A European court dismissed a challenge by a German generics manufacturer, confirming the validity of a patent covering a blood cancer combination therapy.